Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts

BACKGROUND AND AIMS: Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD patients following a switch from the ADA originat...

Descripción completa

Detalles Bibliográficos
Autores principales: Derikx, Lauranne A A P, Dolby, Heather W, Plevris, Nikolas, Lucaciu, Laura, Rees, Caitlin S, Lyons, Mathew, Siakavellas, Spyros I, Constantine-Cooke, Nathan, Jenkinson, Philip, Su, Shanna, O’Hare, Claire, Kirckpatrick, Laura, Merchant, Lynne M, Noble, Colin, Arnott, Ian D, Jones, Gareth-Rhys, Lees, Charlie W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684477/
https://www.ncbi.nlm.nih.gov/pubmed/34089587
http://dx.doi.org/10.1093/ecco-jcc/jjab100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684477/
https://www.ncbi.nlm.nih.gov/pubmed/34089587
http://dx.doi.org/10.1093/ecco-jcc/jjab100

Ejemplares similares